131I-chimeric TNT-1-B monoclonal antibody

06/01/2012 - "A recent Phase II dose-confirmation trial with Cotara for patients with glioblastoma multiforme at first relapse has demonstrated promising overall survival results of 41 weeks. "

06/01/2012 - "One such agent is (131)I-chTNT-1/B mAb (Cotara(®)), a compound locally delivered to the tumor site through convection-enhanced delivery. "
06/01/2005 - "Most patients (88%) were treated with Cotara targeting tumor volume-dependent, single or multiple administrations of activity ranging from 0.5 to 3.0 mCi/cm3 of baseline clinical target volume. "

06/01/2005 - "Between April 1998 and November 2002, 51 patients with histologically confirmed malignant glioma received Cotara by convection-enhanced delivery. "
06/01/2005 - "We report the safety and feasibility of using convection-enhanced delivery to administer Cotara (Peregrine Pharmaceuticals, Inc., Tustin, CA), a novel radioimmunotherapeutic agent, to patients with malignant glioma. "
06/01/2005 - "Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients."
06/01/2012 - "This review explores the clinical experience of radioimmunotherapy and describes the role of Cotara for treatment of patients with malignant gliomas."
06/01/2012 - "Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas."

03/01/2006 - "Overall, a single intravenous dose of Cotara resulted in moderate toxicity, with subjects exhibiting transitory signs of anorexia and vomiting without laboratory evidence of organ pathology. "

03/01/2006 - "Overall, a single intravenous dose of Cotara resulted in moderate toxicity, with subjects exhibiting transitory signs of anorexia and vomiting without laboratory evidence of organ pathology. "